Romidepsin (FK228) fails in counteracting the transformed phenotype of rhabdomyosarcoma cells but efficiently radiosensitizes, in vitro and in vivo, the alveolar phenotype subtype

References

• Akervall J, Brun E, Dictor M, Wennerberg J. 2001. Cyclin D1 overexpression versus response to induction chemotherapy in squamous cell carcinoma of the head and neck–preliminary report. Acta Oncol. 40:505–511.
   PubMed Web of Science ®Google Scholar
• Bharathy N, Berlow NE, Wang E, Abraham J, Settelmeyer TP, Hooper JE, Svalina MN, Bajwa Z, Goros MW, Hernandez BS, et al. 2019. Preclinical rationale for entinostat in embryonal rhabdomyosarcoma. Skelet Muscle. 9:12.
   PubMed Web of Science ®Google Scholar
• Bradley A, Kayton ML, Chi YY, Hawkins DS, Tian J, Breneman J, Woldenc SL, Walterhouse D, Rodeberg DA, Donaldson SS. 2019. Treatment approach and outcomes in infants with localized rhabdomyosarcoma: a report from the soft tissue sarcoma committee of the children’s oncology group. Int J Radiat Oncol Biol Phys. 103:19–27.
   PubMed Web of Science ®Google Scholar
• Buglio D, Khaskhely NM, Voo KS, Martinez-Valdez H, Liu YJ, Younes A. 2011. HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma. Blood. 117(10):2910–2917.
   PubMed Web of Science ®Google Scholar
• Camero S, Camicia L, Marampon F, Ceccarelli S, Shukla R, Mannarino O, Pizer B, Schiavetti A, Pizzuti A, Tombolini V, et al. 2020. BET inhibition therapy counteracts cancer cell survival, clonogenic potential and radioresistance mechanisms in rhabdomyosarcoma cells. Cancer Lett. 479:71–88.
   PubMed Web of Science ®Google Scholar
• Ciccarelli C, Vulcano F, Milazzo L, Gravina GL, Marampon F, Macioce G, Giampaolo A, Tombolini V, Di Paolo V, Hassan HJ, et al. 2016. Key role of MEK/ERK pathway in sustaining tumorigenicity and in vitro radioresistance of embryonal rhabdomyosarcoma stem-like cell population. Mol Cancer. 15:16.
   PubMed Web of Science ®Google Scholar
• Dutta C, Day T, Kopp N, van Bodegom D, Davids MS, Ryan J, Bird L, Kommajosyula N, Weigert O, Yoda A, et al. 2012. BCL2 suppresses PARP1 function and nonapoptotic cell death. Cancer Res. 72:4193–4203.
   PubMed Web of Science ®Google Scholar
• Eberharter A, Becker PB. 2002. Histone acetylation: a switch between repressive and permissive chromatin. Second in review series on chromatin dynamics. EMBO Rep. 3:224–229.
   PubMed Web of Science ®Google Scholar
• El-Naggar AM, Somasekharan SP, Wang Y, Cheng H, Negri GL, Pan M, Wang XQ, Delaidelli A, Rafn B, Cran J, et al. 2019. Class I HDAC inhibitors enhance YB-1 acetylation and oxidative stress to block sarcoma metastasis. EMBO Rep. 20:e48375.
   PubMed Web of Science ®Google Scholar
• Furumai R, Matsuyama A, Kobashi N, Lee KH, Nishiyama M, Nakajima H, Tanaka A, Komatsu Y, Nishino N, Yoshida M, et al. 2002. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res. 62:4916–4921.
   PubMed Web of Science ®Google Scholar
• Gravina GL, Festuccia C, Popov VM, Di Rocco A, Colapietro A, Sanità P, Monache SD, Musio D, De Felice F, Di Cesare E, et al. 2016. c-Myc sustains transformed phenotype and promotes radioresistance of embryonal rhabdomyosarcoma cell lines. Radiat Res. 185:411–422.
   PubMed Web of Science ®Google Scholar
• Gravina GL, Mancini A, Ranieri G, Di Pasquale B, Marampon F, Di Clemente L, Ricevuto E, Festuccia C. 2013. Phenotypic characterization of human prostatic stromal cells in primary cultures derived from human tissue samples. Int J Oncol. 42(6):2116–2122.
   PubMed Web of Science ®Google Scholar
• Gravina GL, Mancini A, Sanita P, Vitale F, Marampon F, Ventura L, Landesman Y, McCauley D, Kauffman M, Shacham S, et al. 2015. KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin in prostate cancer models. BMC Cancer. 15:941.
   PubMed Web of Science ®Google Scholar
• Greider C, Chattopadhyay A, Parkhurst C, Yang E. 2002. BCL-x(L) and BCL2 delay Myc-induced cell cycle entry through elevation of p27 and inhibition of G1 cyclin-dependent kinases. Oncogene. 21:7765–7775.
   PubMed Web of Science ®Google Scholar
• Grobner SN, Worst BC, Weischenfeldt J, Buchhalter I, Kleinheinz K, Rudneva VA, et al. 2018. The landscape of genomic alterations across childhood cancers. Nature. 555:321–327.
   PubMed Web of Science ®Google Scholar
• Groselj B, Sharma NL, Hamdy FC, Kerr M, Kiltie AE. 2013. Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair. Br J Cancer. 108:748–754.
   PubMed Web of Science ®Google Scholar
• Gross A, Katz SG. 2017. Non-apoptotic functions of BCL-2 family proteins. Cell Death Differ. 24:1348–1358.
   PubMed Web of Science ®Google Scholar
• Gryder BE, Wu L, Woldemichael GM, Pomella S, Quinn TR, Park PMC, Cleveland A, Stanton BZ, Song Y, Rota R, et al. 2019. Chemical genomics reveals histone deacetylases are required for core regulatory transcription. Nat Commun. 10:3004.
   PubMed Web of Science ®Google Scholar
• Guha M. 2015. HDAC inhibitors still need a home run, despite recent approval. Nat Rev Drug Discov. 14:225–226.
   PubMed Web of Science ®Google Scholar
• Hedrick E, Crose L, Linardic CM, Safe S. 2015. Histone deacetylase inhibitors inhibit rhabdomyosarcoma by reactive oxygen species-dependent targeting of specificity protein transcription factors. Mol Cancer Ther. 14:2143–2153.
   PubMed Web of Science ®Google Scholar
• Hinson AR, Jones R, Crose LE, Belyea BC, Barr FG, Linardic CM. 2013. Human rhabdomyosarcoma cell lines for rhabdomyosarcoma research: utility and pitfalls. Front Oncol. 3:183.
   PubMedGoogle Scholar
• Hochhauser D, Schnieders B, Ercikan-Abali E, Gorlick R, Muise-Helmericks R, Li WW, Fan J, Banerjee D, Bertino JR. 1996. Effect of cyclin D1 overexpression on drug sensitivity in a human fibrosarcoma cell line. J Natl Cancer Inst. 88(18):1269–1275.
   PubMedGoogle Scholar
• Hontecillas-Prieto L, Flores-Campos R, Silver A, de Álava E, Hajji N, García-Domínguez DJ. 2020. Synergistic enhancement of cancer therapy using HDAC inhibitors: opportunity for clinical trials. Front Genet. 11:578011.
   PubMed Web of Science ®Google Scholar
• Hydbring P, Malumbres M, Sicinski P. 2016. Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases. Nat Rev Mol Cell Biol. 17(5):280–292.
   PubMed Web of Science ®Google Scholar
• Illert AL, Kawaguchi H, Antinozzi C, Bassermann F, Quintanilla-Martinez L, von Klitzing C, Hiwatari M, Peschel C, de Rooij DG, Morris SW, et al. 2012. Targeted inactivation of nuclear interaction partner of ALK disrupts meiotic prophase. Development. 139(14):2523–2534.
   PubMed Web of Science ®Google Scholar
• Jeyakumar M, Liu XF, Erdjument-Bromage H, Tempst P, Bagchi MK. 2007. Phosphorylation of thyroid hormone receptor-associated nuclear receptor corepressor holocomplex by the DNA-dependent protein kinase enhances its histone deacetylase activity. J Biol Chem. 282(13):9312–9322.
   PubMed Web of Science ®Google Scholar
• Kaushal A, Citrin D. 2008. The role of radiation therapy in the management of sarcomas. Surg Clin North Am. 88:629–viii.
   PubMed Web of Science ®Google Scholar
• Kummar S, Gutierrez M, Doroshow JH, Murgo AJ. 2006. Drug development in oncology: classical cytotoxics and molecularly targeted agents. Br J Clin Pharmacol. 62:15–26.
   PubMed Web of Science ®Google Scholar
• Kurmasheva RT, Bandyopadhyay A, Favours E, Del Pozo V, Ghilu S, Phelps DA, Erickson SW, Peer CJ, Figg WD, Smith MA, et al. 2019. Evaluation of entinostat alone and in combination with standard-of-care cytotoxic agents against rhabdomyosarcoma xenograft models. Pediatr Blood Cancer. 66:e27820.
   PubMed Web of Science ®Google Scholar
• Le TV, Seo Y, Ryu CJ, Lee HR, Park HJ. 2010. Increased expression of p27 is associated with the cisplatin resistance in gastric cancer cell line YCC-3. Arch Pharm Res. 33:1127–1132.
   PubMed Web of Science ®Google Scholar
• Lee JH, Choy ML, Marks PA. 2012. Mechanisms of resistance to histone deacetylase inhibitors. Adv Cancer Res. 116:39–86.
   PubMed Web of Science ®Google Scholar
• Lee S, Rauch J, Kolch W. 2020. Targeting MAPK signaling in cancer: mechanisms of drug resistance and sensitivity. Int J Mol Sci. 21(3):1102.
   PubMed Web of Science ®Google Scholar
• Leslie PL, Chao YL, Tsai YH, Ghosh SK, Porrello A, Van Swearingen AED, Harrison EB, Cooley BC, Parker JS, Carey LA, Pecot CV. 2019. Histone deacetylase 11 inhibition promotes breast cancer metastasis from lymph nodes. Nat Commun. 10:4192.
   PubMed Web of Science ®Google Scholar
• Li Y, Seto E. 2016. HDACs and HDAC inhibitors in cancer development and therapy. Cold Spring Harb Perspect Med. 6(10):a026831.
   PubMed Web of Science ®Google Scholar
• Liu R, Chen Y, Liu G, Li C, Song Y, Cao Z, Li W, Hu J, Lu C, Liu Y. 2020. PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers. Cell Death Dis. 11:797.
   PubMed Web of Science ®Google Scholar
• Lombard DB, Cierpicki T, Grembecka J. 2019. Combined MAPK pathway and HDAC inhibition breaks melanoma. Cancer Discov. 9(4):469–471.
   PubMed Web of Science ®Google Scholar
• Mah LJ, El-Osta A, Karagiannis TC. 2010. GammaH2AX: a sensitive molecular marker of DNA damage and repair. Leukemia. 24:679–686.
   PubMed Web of Science ®Google Scholar
• Marampon F, Codenotti S, Megiorni F, Del Fattore A, Camero S, Gravina GL, Festuccia C, Musio D, De Felice F, Nardone V, et al. 2019. NRF2 orchestrates the redox regulation induced by radiation therapy, sustaining embryonal and alveolar rhabdomyosarcoma cells radioresistance. J Cancer Res Clin Oncol. 145:881–893.
   PubMed Web of Science ®Google Scholar
• Marampon F, Di Nisio V, Pietrantoni I, Petragnano F, Fasciani I, Scicchitano BM, Ciccarelli C, Gravina GL, Festuccia C, Del Fattore A, et al. 2019. Pro-differentiating and radiosensitizing effects of inhibiting HDACs by PXD-101 (Belinostat) in in vitro and in vivo models of human rhabdomyosarcoma cell lines. Cancer Lett. 461:90–101.
   PubMed Web of Science ®Google Scholar
• Megiorni F, Gravina GL, Camero S, Ceccarelli s, Del Fattore A, Desiderio V, Papaccio F, McDowell HP, Shukla R, Pizzuti A, et al. 2017. Pharmacological targeting of the ephrin receptor kinase signalling by GLPG1790 in vitro and in vivo reverts oncophenotype, induces myogenic differentiation and radiosensitizes embryonal rhabdomyosarcoma cells. J Hematol Oncol. 10:161.
   PubMed Web of Science ®Google Scholar
• Menegon S, Columbano A, Giordano S. 2016. The dual roles of NRF2 in cancer. Trends Mol Med. 22:578–593.
   PubMed Web of Science ®Google Scholar
• Mirabella AC, Foster BM, Bartke T. 2016. Chromatin deregulation in disease. Chromosoma. 125:75–93.
   PubMed Web of Science ®Google Scholar
• Mirzayans R, Murray D. 2020. Intratumor heterogeneity and therapy resistance: contributions of dormancy, dpoptosis reversal (anastasis) and cell fusion to disease recurrence. Int J Mol Sci. 21(4):1308.
   Web of Science ®Google Scholar
• Oesterle EC, Chien WM, Campbell S, Nellimarla P, Fero ML. 2011. p27(Kip1) is required to maintain proliferative quiescence in the adult cochlea and pituitary. Cell Cycle. 10(8):1237–1248.
   PubMed Web of Science ®Google Scholar
• Pacheco M, Nielsen TO. 2012. Histone deacetylase 1 and 2 in mesenchymal tumors. Mod Pathol. 25(2):222–230.
   PubMed Web of Science ®Google Scholar
• Pal A, Chiu HY, Taneja R. 2019. Genetics, epigenetics and redox homeostasis in rhabdomyosarcoma: emerging targets and therapeutics. Redox Biol. 25:101124.
   PubMed Web of Science ®Google Scholar
• Petragnano F, Pietrantoni I, Camero S, Codenotti S, Milazzo L, Vulcano F, Macioce G, Giordani I, Tini P, Cheleschi S, et al. 2020. Clinically relevant radioresistant rhabdomyosarcoma cell lines: functional, molecular and immune-related characterization. J Biomed Sci. 27:90.
   PubMed Web of Science ®Google Scholar
• Petragnano F, Pietrantoni I, Di Nisio V, Fasciani I, Del Fattore A, Capalbo C, Cheleschi S, Tini P, Orelli S, Codenotti S, et al. 2020. Modulating the dose-rate differently affects the responsiveness of human epithelial prostate- and mesenchymal rhabdomyosarcoma-cancer cell line to radiation. Int J Radiat Biol. 96:823–835.
   PubMed Web of Science ®Google Scholar
• Phelps MP, Bailey JN, Vleeshouwer-Neumann T, Chen EY. 2016. CRISPR screen identifies the NCOR/HDAC3 complex as a major suppressor of differentiation in rhabdomyosarcoma. Proc Natl Acad Sci USA. 113(52):15090–15095.
   PubMed Web of Science ®Google Scholar
• Rahmani M, Aust MM, Benson EC, Wallace L, Friedberg J, Grant S. 2014. PI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo. Clin Cancer Res. 15(18):4849–4860.
   Web of Science ®Google Scholar
• Ray Chaudhuri A, Nussenzweig A. 2017. The multifaceted roles of PARP1 in DNA repair and chromatin remodelling. Nat Rev Mol Cell Biol. 18:610–621.
   PubMed Web of Science ®Google Scholar
• Rixe O, Fojo T. 2007. Is cell death a critical end point for anticancer therapies or is cytostasis sufficient? Clin Cancer Res. 13:7280–7287.
   PubMed Web of Science ®Google Scholar
• Robert C, Rassool FV. 2012. HDAC inhibitors: roles of DNA damage and repair. Adv Cancer Res. 116:87–129.
   PubMed Web of Science ®Google Scholar
• Skapek SX, Ferrari A, Gupta AA, Lupo PJ, Butler E, Shipley J, Barr FG, Hawkins DS. 2019. Rhabdomyosarcoma. Nat Rev Dis Primers. 5(1):1.
   PubMed Web of Science ®Google Scholar
• Strzyz P. 2016. Cell signalling: signalling to cell cycle arrest. Nat Rev Mol Cell Biol. 17:536.
   PubMed Web of Science ®Google Scholar
• Tabackman AA, Frankson R, Marsan ES, Perry K, Cole KE. 2016. Structure of ‘linkerless’ hydroxamic acid inhibitor-HDAC8 complex confirms the formation of an isoform-specific subpocket. J Struct Biol. 195(3):373–378.
   PubMed Web of Science ®Google Scholar
• Taylor SC, Berkelman T, Yadav G, Hammond M. 2013. A defined methodology for reliable quantification of Western blot data. Mol Biotechnol. 55:217–226.
   PubMed Web of Science ®Google Scholar
• Toulany M. 2019. Targeting DNA double-strand break repair pathways to improve radiotherapy response. Genes. 10(1):25.
   PubMed Web of Science ®Google Scholar
• van Erp AEM, Versleijen-Jonkers YMH, van der Graaf WTA, Fleuren EDG. 2018. Targeted therapy-based combination treatment in rhabdomyosarcoma. Mol Cancer Ther. 17:1365–1380.
   PubMed Web of Science ®Google Scholar
• Vleeshouwer-Neumann T, Phelps M, Bammler TK, MacDonald JW, Jenkins I, Chen EY. 2015. Histone deacetylase inhibitors antagonize distinct pathways to suppress tumorigenesis of embryonal rhabdomyosarcoma. PLoS One. 10:e0144320.
   PubMed Web of Science ®Google Scholar
• Vulcano F, Milazzo L, Ciccarelli C, Eramo A, Sette G, Mauro A, Macioce G, Martinelli A, La Torre R, Casalbore P, et al. 2016. Wharton’s jelly mesenchymal stromal cells have contrasting effects on proliferation and phenotype of cancer stem cells from different subtypes of lung cancer. Exp Cell Res. 345:190–198.
   PubMed Web of Science ®Google Scholar
• Wang P, Wang Z, Liu J. 2020. Correction to: role of HDACs in normal and malignant hematopoiesis. Mol Cancer. 19:55.
   PubMed Web of Science ®Google Scholar
• Woods GM, Bondra K, Chronowski C, Leasure J, Singh M, Hensley L, Cripe TP, Chakravarti A, Houghton P. 2015. Radiation therapy may increase metastatic potential in alveolar rhabdomyosarcoma. Pediatr Blood Cancer. 62:1550–1554.
   PubMed Web of Science ®Google Scholar
• Xu WS, Parmigiani RB, Marks PA. 2007. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene. 26(37):5541–5552.
   PubMed Web of Science ®Google Scholar
• Zhang K, Yao Y, Tu Z, Liao C, Wang Z, Qiu Y, Chen D, Hamilton DJ, Li Z, Jiang S. 2020. Discovery of class I histone deacetylase inhibitors based on romidpesin with promising selectivity for cancer cells. Future Med. 12(4):311–323.
   Web of Science ®Google Scholar
• Zhang J, Zhong Q. 2014. Histone deacetylase inhibitors and cell death. Cell Mol Life Sci. 71:3885–3901.
   PubMed Web of Science ®Google Scholar
• Zhao RP, Yu XL, Zhang Z, Jia LJ, Feng Y, Yang ZZ, Chen XX, Wang J, Ma SL, Guo XM. 2016. The efficacy of postoperative radiotherapy in localized primary soft tissue sarcoma treated with conservative surgery. Radiat Oncol. 11:25.
   PubMed Web of Science ®Google Scholar
• Zhou S, Ye W, Shao Q, Zhang M, Liang J. 2013. Nrf2 is a potential therapeutic target in radioresistance in human cancer. Crit Rev Oncol Hematol. 88:706–715.
   PubMed Web of Science ®Google Scholar